Starpharma (ASX: SPL, OTCQX: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured nanoscale molecules. Their unique properties - including their size, structure, high degree of branching, polyvalency, and water solubility - are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer-enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed products.